TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03649633
Drug: isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
Study: NCT03470961
Drug: Anti-Tlymphocyte Globulins
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy regimen in simultaneous pancreas kidney transplantation
Study: NCT03470961
Drug: Anti-Thymocyte Globulins
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy regimen in simultaneous pancreas kidney transplantation
Study: NCT04393285
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib 150mg orally twice a day
Study: NCT04393285
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5mg orally once a day
Study: NCT03890952
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
Study: NCT03890952
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
Study: NCT00997061
Drug: HYCAMTIN
Normalized name: Hycamtin
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observing patients on HYCAMTIN and other drugs for SCLC.
Study: NCT05007093
Drug: Anlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If intolerance occurs, the dose can be downregulated
Study: NCT01933711
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01562158
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two days repeated treatment regimen - low dose administered i.v. (into the vein)
Study: NCT01562158
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
Study: NCT01562158
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two days repeated treatment regimen - high dose administered i.v. (into the vein)
Study: NCT02213042
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
Study: NCT00559754
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg iv on day 1 of each 3 week cycle
Study: NCT00559754
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2 iv on day 1 of each 3 week cycle
Study: NCT02540226
Drug: Intravenous tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02540226
Drug: Topical tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03634644
Drug: Omega 3 fatty acid
Normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega 3 fatty acid,mainly composed of EPA and DHA.
Study: NCT00835159
Drug: Rivastigmine Patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
Study: NCT02215031
Drug: BI 44370
Normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01270542
Drug: Avastin (bevacizumab)
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
Study: NCT00535366
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation by HandiHaler® device
Study: NCT00535366
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral inhalation from Diskus®
Study: NCT00535366
Drug: Fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation from metered dose inhaler (MDI)
Study: NCT00535366
Drug: Ciclesonide low
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral inhalation from MDI
Study: NCT00535366
Drug: Ciclesonide high
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral inhalation from MDI
Study: NCT02080858
Drug: Ticagrelor + Apixaban + ASA
Normalized name: Ticagrelor
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02080858
Drug: Ticagrelor + Apixaban
Normalized name: Ticagrelor
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00576979
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02557945
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
Study: NCT04360421
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient's undergoing major extremity amputation and enrolled in the study as part of the experimental arm will, during their amputation operation, receive liposomal bupivicaine per recommended manufacturing dosing and administration in a field block for long-acting local anesthesia.
Study: NCT00910858
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 5-mg capsules for oral administration
Study: NCT00910858
Drug: Recombinant human erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
Study: NCT02798068
Drug: Solu-medrol or placebo administration
Normalized name: Solu-Medrol
DrugBank: Methylprednisolone hemisuccinate (DB14644)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
Study: NCT02169284
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00251355
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
Study: NCT00251355
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU via continuous IV infusion.
Study: NCT00565981
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally, 40 mg/m2 d1-3 q4w, x4 cycles
Study: NCT00565981
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
Study: NCT01938573
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02269202
Drug: Midazolam, tablet
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01100684
Drug: Asimadoline
Normalized name: Asimadoline
DrugBank: Asimadoline (DB05104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Asimadoline BID
Study: NCT01938573
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01938573
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01649609
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients
Study: NCT01649609
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
Study: NCT00139061
Drug: Torcetrapib/Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00139061
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01522807
Drug: PF-05190457
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
Study: NCT01522807
Drug: PF-05190457
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
Study: NCT01522807
Drug: PF-05190457
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
Study: NCT01522807
Drug: PF-05190457
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
Study: NCT00447603
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
Study: NCT01522807
Drug: PF-05190457
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
Study: NCT02148107
Drug: BI 691751
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 691751 Dose 1
Study: NCT02148107
Drug: BI 691751
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 691751 Dose 2
Study: NCT02148107
Drug: BI 691751
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 691751 Dose 3
Study: NCT02148107
Drug: BI 691751
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 691751 Dose 4
Study: NCT02148107
Drug: BI 691751
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 691751 Dose 5
Study: NCT02148107
Drug: BI 691751
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 691751 Dose 6
Study: NCT00734123
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
Study: NCT00734123
Drug: Aspirin or clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aspirin 100 mg or clopidogrel 75 mg/ per day
Study: NCT00447603
Drug: Placebo for Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01381900
Drug: Canagliflozin 100mg
Normalized name: CANAGLIFLOZIN 100MG TAB
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
Study: NCT01381900
Drug: Canagliflozin 300mg
Normalized name: CANAGLIFLOZIN 300MG TAB
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
Study: NCT01381900
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The participant's stable dose of background therapy of metformin should be continued throughout the study.
Study: NCT00734123
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care
Study: NCT00185068
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00374543
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
Study: NCT00185068
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02025166
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain treatment with aniline analgesics (paracetamol) at the time of the procedure
Study: NCT00965809
Drug: Tetrahydrocannabinol
Normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
Study: NCT01368276
Drug: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 µg/m² subcutaneous injection
Study: NCT04060030
Drug: Levoleucovorin Calcium
Normalized name: Levoleucovorin Calcium
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid leucovorin calcium dosed by weight
Study: NCT02835560
Drug: Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid
Study: NCT01474369
Drug: TAK-438
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
Study: NCT01474369
Drug: TAK-438
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
Study: NCT00110981
Drug: Etanerept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
Study: NCT00110981
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
Study: NCT02328651
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.~For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg, iv, Bid\~tid）
Study: NCT03539003
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of sevoflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
Study: NCT01130103
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
Study: NCT01230710
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib was supplied as tablets.
Study: NCT03078374
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dosage to obtain lower INR range
Study: NCT02425904
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: second-generation purine nucleoside analog
Study: NCT03189498
Drug: JNJ-64041575
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250 mg tablets) on Day 1.
Study: NCT03656510
Drug: JNJ-53718678
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-53718678 (high dose or low dose) orally twice daily for 7 days.
Study: NCT00001443
Drug: indinavir (MK-0639)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01427920
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
Study: NCT00352443
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
Study: NCT00352443
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
Study: NCT01710488
Drug: Levofloxacin 1 tablet 500 mg once a day
Normalized name: levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.
Study: NCT01710488
Drug: Prulifloxacin 1 tablet 600 mg once a day
Normalized name: Orbifloxacin Tablets
DrugBank: Prulifloxacin (DB11892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.
Study: NCT01313390
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01313390
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04137107
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given standard of care oxaliplatin
Study: NCT04137107
Drug: Duloxetine Hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04137107
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO